CL COLGATE PALMOLIVE CO
Perfumes, Cosmetics & Other Toilet Preparations · NYSE · SEC CIK 21665 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.9%
TTM net income YoY-29.4%
TTM EPS YoY-28.0%
Revenue 3-yr CAGR3.6%
Net income 3-yr CAGR9.0%
Margins
Gross margin60.6%
Operating margin14.8%
Net margin9.6%
FCF margin17.8%
EBITDA margin17.9%
Returns
ROE358.9%
ROA12.0%
ROIC (approx.)36.1%
Asset turnover1.24x
Leverage & solvency
Liabilities / assets96.2%
Debt / equity24.94x
Current ratio0.96x
Interest coverage12.64x
Cash quality & payout
Operating cash flow / net income2.13x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $20.38B | $20.10B | $19.46B | $17.97B | $17.42B |
| Cost of revenue | $8.13B | $7.94B | $8.13B | $7.72B | $7.05B |
| Gross profit | $12.25B | $12.16B | $11.33B | $10.25B | $10.38B |
| R&D expense | $366.00M | $355.00M | $343.00M | $320.00M | $307.00M |
| SG&A expense | $7.90B | $7.73B | $7.15B | $6.57B | $6.41B |
| Operating income | $3.31B | $4.27B | $3.98B | $2.89B | $3.33B |
| Interest expense | $267.00M | $292.00M | $287.00M | $167.00M | $120.00M |
| Pretax income | $3.06B | $3.96B | $3.39B | $2.66B | $3.09B |
| Income tax | $798.00M | $907.00M | $937.00M | $693.00M | $749.00M |
| Net income | $2.13B | $2.89B | $2.30B | $1.78B | $2.17B |
| EBITDA | $3.94B | $4.87B | $4.55B | $3.44B | $3.89B |
| EPS (basic) | 2.64 | 3.53 | 2.78 | 2.13 | 2.56 |
| EPS (diluted) | 2.63 | 3.51 | 2.77 | 2.13 | 2.55 |
| Dividends declared per share | 2.08 | 2.48 | 1.91 | 1.86 | 1.79 |
| Weighted avg. shares (diluted) | 811.10M | 823.20M | 829.20M | 838.80M | 848.30M |
| Balance sheet | |||||
| Cash & equivalents | $1.29B | $1.10B | $966.00M | $775.00M | $832.00M |
| Short-term investments | $107.00M | $160.00M | $179.00M | — | — |
| Receivables | $1.68B | $1.52B | $1.59B | $1.50B | $1.30B |
| Inventory | $2.03B | $1.99B | $1.93B | $2.07B | $1.69B |
| Current assets | $5.71B | $5.32B | $5.28B | $5.11B | $4.40B |
| PP&E, net | $4.66B | $4.42B | $4.58B | $4.31B | $3.73B |
| Goodwill | $3.12B | $3.27B | $3.41B | $3.35B | $3.28B |
| Intangibles | $1.54B | $1.76B | $1.89B | $1.92B | $2.46B |
| Total assets | $16.33B | $16.05B | $16.39B | $15.73B | $15.04B |
| Current liabilities | $6.85B | $5.76B | $4.74B | $4.00B | $4.05B |
| Short-term debt | $1.11B | $652.00M | $20.00M | $14.00M | $12.00M |
| Long-term debt | $6.87B | $7.29B | $8.22B | $8.74B | $7.19B |
| Total debt | $7.99B | $7.94B | $8.24B | $8.76B | $7.21B |
| Total liabilities | $15.96B | $15.50B | $15.44B | $14.93B | $14.07B |
| Shareholders' equity | $54.00M | $212.00M | $609.00M | $401.00M | $609.00M |
| Net debt | $6.70B | $6.84B | $7.27B | $7.98B | $6.37B |
| Shares outstanding | 801.24M | 812.57M | 821.41M | 830.21M | 840.48M |
| Cash flow statement | |||||
| Operating cash flow | $4.20B | $4.11B | $3.75B | $2.56B | $3.33B |
| Capital expenditure | $564.00M | $561.00M | $705.00M | $696.00M | $567.00M |
| Free cash flow | $3.63B | $3.55B | $3.04B | $1.86B | $2.76B |
| Investing cash flow | -$817.00M | -$534.00M | -$742.00M | -$1.60B | -$592.00M |
| Financing cash flow | -$3.26B | -$3.39B | -$2.79B | -$952.00M | -$2.77B |
| Depreciation & amortization | $630.00M | $605.00M | $567.00M | $545.00M | $556.00M |
| Stock-based compensation | $155.00M | $135.00M | $122.00M | $125.00M | $135.00M |
| Share buybacks | $1.21B | $1.74B | $1.13B | $1.31B | $1.32B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.